A Peripartum Cardiomyopathy Case Treated with Bromocriptine

Günay Ş., Serdar O. A., Yeşilbursa D., Güllülü N. S., Bolca Topal N.

17. Uludağ İç Hastalıkları Kış Kongresi, Bursa, Turkey, 05 March 2021, pp.117-119

  • Publication Type: Conference Paper / Full Text
  • City: Bursa
  • Country: Turkey
  • Page Numbers: pp.117-119
  • Bursa Uludag University Affiliated: Yes


Introduction: Peripartum cardiomyopathy is a rare disease that is difficult to diagnose and treat. Clinical findings are similar with heart failure. New treatments are needed in addition to the treatment of heart failure.

Case Report: A 32-year-old woman presented with symptoms of heart failure 4 days after first delivery. Chest X-ray showed cardiomegaly. Serum BNP level was high. Transthoracic echocardiography (TTE) indicated dilated left atrium and left ventricle, severe mitral regurgitation and ventricular dysfunction. The global longitudinal strain was – 9.1%. Cardiac magnetic resonance imaging (MRI) revealed mid-myocardial staining detected in late phase images. Concomitant bromocriptine (2,5 mg po twice a day for 15 days and then 2,5 mg po once a day for 15 days) was used with standard heart failure therapy. At 6 months, TTE and cardiac MRI revealed normal biventricular function and size. Global longitudinal strain was –14%.

Conclusion: Patients with peripartum cardiomyopathy may benefit from bromocriptine.